Dominari (NASDAQ:DOMH – Get Free Report) and Associated Capital Group (NYSE:AC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.
Analyst Ratings
This is a breakdown of current ratings and target prices for Dominari and Associated Capital Group, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Dominari | 0 | 0 | 0 | 0 | N/A |
Associated Capital Group | 0 | 1 | 5 | 0 | 2.83 |
Associated Capital Group has a consensus price target of $27.50, indicating a potential downside of 14.46%. Given Associated Capital Group’s higher possible upside, analysts clearly believe Associated Capital Group is more favorable than Dominari.
Insider and Institutional Ownership
Risk and Volatility
Dominari has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Associated Capital Group has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
Earnings & Valuation
This table compares Dominari and Associated Capital Group’s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Dominari | $2.04 million | 6.74 | -$22.88 million | ($4.44) | -0.52 |
Associated Capital Group | $12.68 million | 54.49 | $37.45 million | $1.72 | 18.69 |
Associated Capital Group has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Associated Capital Group, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Dominari and Associated Capital Group’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Dominari | N/A | -37.80% | -34.85% |
Associated Capital Group | 295.29% | 4.15% | 4.00% |
Summary
Associated Capital Group beats Dominari on 11 of the 13 factors compared between the two stocks.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
About Associated Capital Group
Associated Capital Group, Inc., together with its subsidiaries, provides investment advisory services in the United States. The company offers alternative investment management services; and operates a direct investment business. It also invests in new and existing businesses. The company was founded in 1976 and is headquartered in Greenwich, Connecticut. Associated Capital Group, Inc. operates as a subsidiary of GGCP Holdings LLC.
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.